Assess whether scientific advice should be sought before the next trial

Situation

A CMO 483 that maps to the NDA CMC module put disproportionate reporting signal workbook in front of CMC change-control owner in a mid-size sponsor after a complete response letter. This Pharma & Life Sciences / Pharmacovigilance close is scientific advice should be from disproportionate reporting signal workbook, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• CMC change-control owner can defend Proceed under protocol from disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module in a Pharma & Life Sciences challenge.
• CMC change-control owner cannot defend Proceed under protocol from disproportionate reporting signal workbook; Pause the pathway is what the extract actually supports after a CMO 483 that maps to the NDA CMC module.
• A CMO 483 that maps to the NDA CMC module never reached the population in disproportionate reporting signal workbook — reopen intake, do not close scientific advice should be.
• Two facts in disproportionate reporting signal workbook after a CMO 483 that maps to the NDA CMC module conflict for CMC change-control owner; hold this Pharmacovigilance file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether disproportionate reporting signal workbook supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• For this Pharma & Life Sciences Pharmacovigilance file, read disproportionate reporting signal workbook against a CMO 483 that maps to the NDA CMC module and write the one fact that would move scientific advice should be for CMC change-control owner.

Recommendation

Proceed under protocol is the Pharma & Life Sciences Pharmacovigilance move when disproportionate reporting signal workbook lines up with a CMO 483 that maps to the NDA CMC module for CMC change-control owner in a mid-size sponsor after a complete response letter. Pause the pathway is the move when that alignment in disproportionate reporting signal workbook fails. Record the missing fact in disproportionate reporting signal workbook before anyone treats scientific advice should be as closed.